Trials / Completed
CompletedNCT03013543
Setmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of Obesity
Setmelanotide (RM-493) Phase 2 Treatment Trial in Patients With Rare Genetic Disorders of Obesity
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 213 (actual)
- Sponsor
- Rhythm Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 6 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study was to determine the effect of setmelanotide (RM-493) on weight, hunger assessments, and other factors in participants with rare genetic disorders of obesity.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Setmelanotide | RM-493 QD SC injection |
Timeline
- Start date
- 2017-02-10
- Primary completion
- 2022-03-01
- Completion
- 2022-03-01
- First posted
- 2017-01-06
- Last updated
- 2023-08-18
- Results posted
- 2023-08-18
Locations
58 sites across 9 countries: United States, Canada, France, Germany, Greece, Israel, Netherlands, Spain, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03013543. Inclusion in this directory is not an endorsement.